Hypertrophic Cardiomyopathy
Top Cited Papers
- 6 May 2003
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 107 (17) , 2227-2232
- https://doi.org/10.1161/01.cir.0000066323.15244.54
Abstract
Background— Hypertrophic cardiomyopathy is an autosomal-dominant disorder in which 10 genes and numerous mutations have been reported. The aim of the present study was to perform a systematic screening of these genes in a large population, to evaluate the distribution of the disease genes, and to determine the best molecular strategy in clinical practice. Methods and Results— The entire coding sequences of 9 genes ( MYH7 , MYBPC3 , TNNI3 , TNNT2 , MYL2 , MYL3 , TPM1 , ACTC , and TNNC1 ) were analyzed in 197 unrelated index cases with familial or sporadic hypertrophic cardiomyopathy. Disease-causing mutations were identified in 124 index patients (≈63%), and 97 different mutations, including 60 novel ones, were identified. The cardiac myosin-binding protein C ( MYBPC3 ) and β-myosin heavy chain ( MYH7 ) genes accounted for 82% of families with identified mutations (42% and 40%, respectively). Distribution of the genes varied according to the prognosis ( P =0.036). Moreover, a mutation was found in 15 of 25 index cases with “sporadic” hypertrophic cardiomyopathy (60%). Finally, 6 families had patients with more than one mutation, and phenotype analyses suggested a gene dose effect in these compound-heterozygous, double-heterozygous, or homozygous patients. Conclusion— These results might have implications for genetic diagnosis strategy and, subsequently, for genetic counseling. First, on the basis of this experience, the screening of already known mutations is not helpful. The analysis should start by testing MYBPC3 and MYH7 and then focus on TNNI3 , TNNT2 , and MYL2 . Second, in particularly severe phenotypes, several mutations should be searched. Finally, sporadic cases can be successfully screened.Keywords
This publication has 18 references indexed in Scilit:
- Genetic testing and genetic counselling in hypertrophic cardiomyopathy: the French experienceJournal of Medical Genetics, 2002
- Disease-Causing Mutations in Cardiac Troponin T: Identification of a Critical Tropomyosin-Binding RegionBiophysical Journal, 2001
- Identification of a Gene Responsible for Familial Wolff–Parkinson–White SyndromeNew England Journal of Medicine, 2001
- Mutations in the gamma2 subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesisHuman Molecular Genetics, 2001
- The Molecular Genetic Basis for Hypertrophic CardiomyopathyJournal of Molecular and Cellular Cardiology, 2001
- Familial Hypertrophic Cardiomyopathy Mutations in the Regulatory Light Chains of Myosin Affect Their Structure, Ca2+Binding, and PhosphorylationJournal of Biological Chemistry, 2001
- Homozygotes for a R869G Mutation in the β -myosin Heavy Chain Gene have a Severe Form of Familial Hypertrophic CardiomyopathyJournal of Molecular and Cellular Cardiology, 2000
- Sudden Death due to Troponin T MutationsJournal of the American College of Cardiology, 1997
- A new missense mutation, Arg719Gln, in the β-cardiac heavy chain myosin gene of patients with familial hypertrophic cardiomyopathyHuman Molecular Genetics, 1994
- Identification of a new missense mutation at Arg403, a CpG mutation hotspot, in exon 13 of the β-myosin heavy chain gene in hypertrophic cardiomyopathyHuman Molecular Genetics, 1993